文献速递泌尿生殖腹部CT

小肾肿块(≤ 4 cm):利用对比增强CT上病灶与皮质衰减比值及主动脉-病灶衰减差鉴别嗜酸细胞瘤与肾透明细胞癌

Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta-lesion attenuation difference (ALAD) on contrast-enhanced CT.
PubMed 文献 · Radiol Med · 2020-05-08

回顾性纳入76例术前接受多期对比增强CT的小肾肿块(直径<4 cm)患者,比较嗜酸细胞瘤与透明细胞肾细胞癌的病灶/皮质衰减比值(L/C)和主动脉-病灶衰减差(ALAD)。皮髓质期嗜酸细胞瘤L/C为0.92±0.12、透明细胞肾细胞癌为0.69±0.20(p<0.01),诊断嗜酸细胞瘤准确率80%;肾图期嗜酸细胞瘤L/C降至0.78±0.11而透明细胞肾细胞癌为0.69±0.13(p=0.025),准确率65%。作者认为皮髓质期L/C比值可能有助于鉴别两者。

要点

  • 皮髓质期L/C比值嗜酸细胞瘤0.92±0.12 vs 透明细胞肾细胞癌0.69±0.20(p<0.01),诊断嗜酸细胞瘤准确率80%。
  • 肾图期嗜酸细胞瘤L/C降至0.78±0.11呈早期廓清,透明细胞肾细胞癌为0.69±0.13(p=0.025),准确率65%。
  • 肾图期ALAD嗜酸细胞瘤21.95±16.24 vs 透明细胞肾细胞癌36.96±30.53(p=0.049)。

核心结论

  • 皮髓质期病灶/皮质衰减比值可能有助于鉴别嗜酸细胞瘤与透明细胞肾细胞癌。

研究设计与样本

  • 回顾性研究,纳入2014年1月至2018年12月术前接受CT检查的76例可疑小肾肿块(直径<4 cm)患者,术后病理诊断嗜酸细胞瘤21例、透明细胞肾细胞癌25例、嫌色细胞肾细胞癌7例、乳头状肾细胞癌7例、多房囊性肾细胞癌7例、血管平滑肌脂肪瘤7例、平滑肌瘤2例。
  • 由两名放射科医师独立在同一层面放置圆形感兴趣区,测量肿瘤、正常肾皮质和主动脉的CT衰减值。

关键影像表现/征象

  • 皮髓质期嗜酸细胞瘤强化与肾皮质等密度(L/C比值0.92±0.12),透明细胞肾细胞癌相对肾皮质低密度(L/C比值0.69±0.20;p<0.01)。
  • 肾图期嗜酸细胞瘤L/C比值0.78±0.11,低于其皮髓质期,呈早期廓清表现;透明细胞肾细胞癌L/C比值0.69±0.13,与皮髓质期相近(p=0.025)。
  • 排泄期L/C比值在嗜酸细胞瘤与透明细胞肾细胞癌间重叠明显(p=0.27)。

诊断标准与关键数值

  • 皮髓质期L/C比值诊断嗜酸细胞瘤准确率80%,肾图期L/C比值诊断嗜酸细胞瘤准确率65%。
  • 肾图期ALAD值嗜酸细胞瘤21.95±16.24,透明细胞肾细胞癌36.96±30.53(p=0.049)。

临床应用与阅片要点

  • 作者认为皮髓质期病灶/皮质衰减比值可能有助于鉴别嗜酸细胞瘤与透明细胞肾细胞癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: We investigate the use of ratio of lesion to cortex (L/C) attenuation and aorta-lesion attenuation difference (ALAD) on multiphase contrast-enhanced CT to help distinguish oncocytoma from clear cell RCC in small renal masses (diameter < 4 cm).

METHODS: We retrospectively identified 76 patients that undergo CT before surgery for a suspicious small renal mass between January 2014 and December 2018 with pathological diagnosis of 21 oncocytomas (ROs), 25 clear cell RCCs, 7 chromophobe RCCs, 7 papillary RCCs, 7 multilocular cystic RCCs, 7 angiomyolipomas and 2 leiomyomas. CT attenuation values were obtained for the tumor, the normal renal cortex and the aorta, placing a circular region of interest (ROI) in the same slice by two radiologists, independently.

RESULTS: In the corticomedullary phase, ROs showed isodense enhancement to the renal cortex (ratio L/C 0.92 ± 0.12), while clear cell RCCs appeared hypodense to the renal cortex (ratio L/C 0.69 ± 0.20; p < 0.01) with an accuracy of 80% for diagnosing RO. In nephrographic phase, the ratio L/C attenuation was lower than the corticomedullary phase in ROs (0.78 ± 0.11) showing an early washout pattern, while the ratio L/C was similar to the corticomedullary phase in clear cell RCCs (0.69 ± 0.13; p = 0.025, with an accuracy of 65% for diagnosing RO). The ratio L/C attenuation showed considerable overlap between ROs and clear cell RCCs in the excretory phase (p = 0.27). Mean ALAD values in the nephrographic phase were 21.95 ± 16.24 for ROs and 36.96 ± 30.53 for clear cell RCCs (p = 0.049).

CONCLUSION: The ratio L/C attenuation in corticomedullary phase may be useful to differentiate RO from clear cell RCC.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Gentili F, Bronico I, Maestroni U, et al. Small renal masses (≤ 4 cm): differentiation of oncocytoma from renal clear cell carcinoma using ratio of lesion to cortex attenuation and aorta-lesion attenuation difference (ALAD) on contrast-enhanced CT. Radiol Med. 2020. PMID: 32385827. doi:10.1007/s11547-020-01199-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。